Jenna Li is a Vice President in Investment Banking at Jefferies, specializing in capital markets transactions and advisory services. While her specific company coverage, performance metrics, and investment track record are not publicly detailed, she holds a leadership role within the firm based in New York. Jenna joined Jefferies after developing her expertise in financial analysis and strategic consulting, contributing to key investment banking projects for the firm’s global client base. Her professional credentials and securities licensing status are not specified in the available records.
Jenna Li asked about the rationale behind initiating the adjuvant study (Resolute 304) before the first-line study (Resolute 303).
Mark Goldsmith, Chairman and CEO, explained that the adjuvant study is simpler, with a single treatment arm, allowing it to be initiated earlier. He noted that this sequencing would not materially affect the overall conduct of the trials, though the adjuvant study is expected to have a longer readout timeline.
Jenna Li asked about the rationale behind starting the adjuvant study (Resolute 304) before the first-line study.
Mark Goldsmith, Chairman and CEO, explained that Resolute 304 is a simpler study with a single treatment arm, allowing it to be initiated earlier. He noted that this timing difference would not materially impact the overall conduct, though the readout for the adjuvant study would naturally be longer.
Jenna Li from Jefferies, on behalf of Kelly Hsu, asked about the expected durability of the high complete response rates observed in the LOTUS-5 and LOTUS-7 trials. She sought clarity on the potential incremental durability benefit versus glufitamab monotherapy and what early durability metrics might be shared in the next LOTUS-7 update.
Chief Medical Officer Mohamed Zaki explained that high complete response (CR) rates are a strong surrogate for durability and noted that 25 of 26 CR patients in LOTUS-7 remained in response at the data cutoff. He mentioned both ZYNLONTA and glufitamab have shown significant durability as single agents. CEO Ameet Mallik added that future data updates will include updated Swimmer's plots and, as data matures, metrics on the median duration of CR at six and twelve months.
Speaking on behalf of Michael Yee, the analyst asked for specific details on the early launch, including the magnitude of orders, shipment status, and the timing for booking sales.
The company declined to provide specific early launch metrics, stating that it is too early to provide data that would be informative for the full year. They noted they are encouraged by what they are seeing and will provide more detailed updates on sales and trends as the launch progresses, likely in the summer or fall.
Jenna Li, on behalf of Michael Yee at Jefferies, asked about the magnitude of PEMGARDA orders, shipment status, and the timing for booking sales.
Marc Elia, Chairman, stated that while the company is encouraged by early launch progress, it is too early to provide specific details on order volumes or sales trends. He indicated that more informative updates would be provided in the summer and fall as the launch matures.
Performance on expert-authored financial analysis tasks